Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin,
and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their …

Abstract Sodium-glucose co-transporter 2 (SGLT2) inhibitors are glucose-lowering drugs
that reduce plasma glucose levels by inhibiting glucose and sodium reabsorption in the …

Aims In patients with cardiovascular disease, epicardial adipose tissue (EAT) is
characterized by insulin resistance, high pro-inflammatory chemokines, and low …

Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD) worldwide.
Glycemic and blood pressure (BP) control are important but not sufficient to attenuate the …

Abstract Purpose of the Review Hyperactivity of sympathetic nervous system (SNS) plays a
role in the development of arterial hypertension and heart failure, two co-morbidities …

The main cause of death in patients with type 2 DM is cardiovascular complications resulting
from the progression of atherosclerosis. The pathophysiology of the association between …

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of antidiabetic oral
agents indicating promising effects on cardiovascular and renal end points. However, the …

Recent clinical trials have demonstrated a strong cardiovascular (CV) protective effect of
sodium/glucose cotransporter (SGLT) 2 inhibitors, a recently introduced class of …

Background Recent studies have shown that sodium-glucose cotransporter-2 inhibitors
(SGLT2i) can achieve significant improvement in blood pressure in people with diabetes …

Hypertension and type 2 diabetes mellitus (T2DM) are risk factors for cardiovascular
disease. Dapagliflozin improves glycemic control and systolic blood pressure (SBP) in …